Emerging roles for vasoactive peptides in diagnostic and therapeutic strategies against atherosclerotic cardiovascular diseases

Current Protein and Peptide Science

Volumn 14, Issue 6, 2013, Pages 472-480

  Watanabe, Takuya ^a   Sato, Kengo ^a   Itoh, Fumiko ^a   Noguchi, Yuri ^a   Fujimoto, Kazumi ^b   Koyama, Takatoshi ^b   Shichiri, Masayoshi ^c  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Atherosclerosis; Biomarker; Coronary artery disease; Glucagon like peptide 1; Heregulin 1; Salusins; Urotensin II

Indexed keywords

4 AMINOQUINOLINE; ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN II ANTAGONIST; CANDESARTAN; CHOLESTEROL ACYLTRANSFERASE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEREGULIN BETA 1 ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PALOSURAN; PEPTIDES AND PROTEINS; SALUSIN ALPHA ANTAGONIST; SALUSIN BETA; SARPOGRELATE; SEROTONIN; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROTENSIN II; UROTENSIN RECEPTOR ANTAGONIST; VASCULAR CELL ADHESION MOLECULE 1; VASOACTIVE AGENT; ANGIOTENSIN II; BIOLOGICAL MARKER; HEREGULIN BETA1; NEU DIFFERENTIATION FACTOR; SIGNAL PEPTIDE; TOR2A PROTEIN, HUMAN; UROTENSIN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CHOLESTEROL DIET; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEART FAILURE; HEART PROTECTION; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INSULIN RELEASE; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; REPERFUSION INJURY; SENSITIVITY AND SPECIFICITY; ANIMAL; BLOOD; METABOLISM; MOLECULARLY TARGETED THERAPY;

ADIPONECTIN; ANGIOTENSIN II; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR TARGETED THERAPY; NEUREGULIN-1; SEROTONIN; UROTENSINS;

EID: 84887479682     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/13892037113149990064     Document Type: Article

References (118)

1. Schachter, M. The pathogenesis of atherosclerosis. Int. J. Cardiol., 1997, 62 Suppl 2, S3-S7.
2. Allahverdian, S.; Pannu, P.S.; Francis, G.A. Contribution of monocyte-derived macrophages and smooth muscle cells to arterial foam cell formation. Cardiovasc. Res., 2012, 95, 165-172.
3. Weber, C.; Noels, H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med., 2011, 17, 1410-1422.
4. Selvaraj, C.L.; van de Graaff, E.J.; Campbell, C.L.; Abels, B.S.; Marshall, J.P.; Steinhubl, S.R. Point-of-care determination of baseline platelet function as a predictor of clinical outcomes in patients who present to the emergency department with chest pain. J. Thromb. Thrombolysis, 2004, 18, 109-115.
5. Zakynthinos, E.; Pappa, N. Inflammatory biomarkers in coronary artery disease. J. Cardiol., 2009, 53, 317-333.
6. Hochholzer, W.; Morrow, D.A.; Giugliano, R.P. Novel biomarkers in cardiovascular disease: Update 2010. Am. Heart J., 2010, 160, 583-594.
7. Mitra, B.; Panja, M. High sensitive C-reactive protein: a novel biochemical markers and its role in coronary artery disease. J. Assoc. Physicians India, 2005, 53, 25-32.
8. Corrado, E.; Rizzo, M.; Coppola, G.; Fattouch, K.; Novo, G.; Marturana, I.; Ferrara, F.; Novo, S. An update on the role of markers of inflammation in atherosclerosis. J. Atheroscler. Thromb., 2010, 17, 1-11.
9. Nagesh, C.M.; Roy, A. Role of biomarkers in risk stratification of acute coronary syndrome. Indian J. Med. Res., 2010, 132, 627-633.
10. Tsimikas, S. Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. Am. J. Cardiol., 2006, 98 Suppl, 9-17.
11. Watanabe, T.; Koba, S. Roles of serotonin in atherothrombosis and related diseases. In: Traditional and Novel Risk Factors in Atherothrombosis; Efrain Gaxiola, Ed.; InTech: Rijeka, Croatia, 2012; pp. 57-70.
12. Watanabe, T.; Arita, S.; Shiraishi, Y.; Suguro, T.; Sakai, T.; Hongo, S.; Miyazaki, A. Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases. Curr. Med. Chem., 2009, 16, 550-563.
13. Watanabe, T.; Sato, K.; Itoh, F.; Wakabayashi, K.; Shichiri, M.; Hirano T. Endogenous bioactive peptides as potential biomarkers for atherosclerotic coronary heart disease. Sensors (Basel), 2012, 12, 4974-4985.
14. Barseghian, A.; Gawande, D.; Bajaj, M. Adiponectin and vulnerable atherosclerotic plaques. J. Am. Coll. Cardiol., 2011, 57, 761-770.
15. Watanabe, T.; Sato, K.; Itoh, F.; Iso, Y. Pathogenic involvement of heregulin-β1 in anti-atherogenesis. Regul. Pept., 2012, 175, 11-14.
16. Nagashima, M.; Watanabe, T.; Terasaki, M.; Tomoyasu, M.; Nohtomi, K.; Kim-Kaneyama, J.; Miyazaki, A.; Hirano T. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia, 2011, 54, 2649-2659.
17. Shichiri, M.; Ishimaru, S.; Ota, T.; Nishikawa, T.; Isogai, T.; Hirata, Y. Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat. Med., 2003, 9, 1166-1172.
18. Yoshimura, M.; Yasue, H.; Ogawa, H. Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Can. J. Physiol. Pharmacol., 2001, 79, 730-735.
19. Rademaker, M.T.; Cameron, V.A.; Charles, C.J.; Lainchbury, J.G.; Nicholls, M.G.; Richards, A.M. Adrenomedullin and heart failure. Regul. Pept., 2003, 112, 51-60.
20. Sata, M.; Fukuda, D. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. J. Med. Invest., 2010, 57, 12-25.
21. Watanabe, T.; Sato, K.; Itoh, F.; Iso, Y.; Nagashima, M.; Hirano, T.; Shichiri, M. The roles of salusins in atherosclerosis and related cardiovascular diseases. J. Am. Soc. Hypertens., 2011, 5, 359-365.
22. Drucker, D.J. The biology of incretin hormones. Cell Metab., 2006, 3, 153-165.
23. Xu, G.; Watanabe, T.; Iso, Y.; Koba, S.; Sakai, T.; Nagashima, M.; Arita, S.; Hongo, S.; Ota, H.; Kobayashi, Y.; Miyazaki, A.; Hirano, T. Preventive effects of heregulin-β1 on macrophage foam cell formation and atherosclerosis. Circ. Res., 2009, 105, 500-510.
24. Ouchi, N.; Walsh, K. Adiponectin as an anti-inflammatory factor. Clin. Chim. Acta, 2007, 380, 24-30.
25. Xu, Z.; Ford, G.D.; Croslan, D.R.; Jiang, J.; Gates, A.; Allen, R.; Ford, B.D. Neuroprotection by neuregulin-1 following focal stroke is associated with the attenuation of ischemia-induced proinflammatory and stress gene expression. Neurobiol. Dis., 2005, 19, 461-470.
26. Motoshima, H.; Wu, X.; Mahadev, K.; Goldstein, B.J. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem. Biophys. Res. Commun., 2004, 315, 264-271.
27. Timolati, F.; Ott, D.; Pentassuglia, L.; Giraud, M.N.; Perriard, J.C.; Suter, T.M.; Zuppinger, C. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J. Mol. Cell. Cardiol., 2006, 41, 845-854.
28. Liu, F.Q.; Zhang, X.L.; Gong, L.; Wang, X.P.; Wang, J.; Hou, X.G.; Sun, Y.; Qin, W.D.; Wei, S.J.; Zhang, Y.; Chen, L.; Zhang, M.X. Glucagon-like peptide 1 protects microvascular endothelial cells by inactivating the PARP-1/iNOS/NO pathway. Mol. Cell. Endocrinol., 2011, 339, 25-33.
29. Cheng, K.K.; Lam, K.S.; Wang, Y.; Huang, Y.; Carling, D.; Wu, D.; Wong, C.; Xu, A. Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes, 2007, 56, 1387-1394.
30. Brero, A.; Ramella, R.; Fitou, A.; Dati, C.; Alloatti, G.; Gallo, M.P.; Levi, R. Neuregulin-1β1 rapidly modulates nitric oxide synthesis and calcium handling in rat cardiomyocytes. Cardiovasc. Res., 2010, 88, 443-452.
31. Ding, L.; Zhang, J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol. Sin., 2012, 33, 75-81.
32. Shibata, R.; Izumiya, Y.; Sato, K.; Papanicolaou, K.; Kihara, S.; Colucci, W.S.; Sam, F.; Ouchi, N.; Walsh, K. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J. Mol. Cell. Cardiol., 2007, 42, 1065-1074.
33. Hedhli, N.; Huang, Q.; Kalinowski, A.; Palmeri, M.; Hu, X.; Russell, R.R.; Russell, K.S. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation, 2011, 123, 2254-2262.
34. Nikolaidis, L.A.; Doverspike, A.; Hentosz, T.; Zourelias, L.; Shen, Y.T.; Elahi, D.; Shannon, R.P. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J. Pharmacol. Exp. Ther., 2005, 312, 303-308.
35. Matsuzawa, Y. Adiponectin: A key player in obesity related disorders. Curr. Pharm. Des., 2010, 16, 1896-1901.
36. Kanome, T.; Watanabe, T.; Nishio, K.; Takahashi, K.; Hongo, S.; Miyazaki, A. Angiotensin II upregulates acyl-CoA:cholesterol acyltransferase-1 via the angiotensin II type 1 receptor in human monocyte-macrophages. Hypertens. Res., 2008, 31, 1801-1810.
37. Watanabe, T.; Suguro, T.; Kanome, T.; Sakamoto, Y.; Kodate, S.; Hagiwara, T.; Hongo, S.; Hirano, T.; Adachi, M.; Miyazaki, A. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension, 2005, 46, 738-744.
38. Watanabe, T.; Nishio, K.; Kanome, T.; Matsuyama, T.; Koba, S.; Sakai, T.; Sato, K.; Hongo, S.; Nose, K.; Ota, H.; Kobayashi, Y.; Katagiri, T.; Shichiri, M.; Miyazaki, A. Impact of salusin-α and-β on human macrophage foam cell formation and coronary atherosclerosis. Circulation, 2008, 117, 638-648.
39. Furukawa, K.; Hori, M.; Ouchi, N.; Kihara, S.; Funahashi, T.; Matsuzawa, Y.; Miyazaki, A.; Nakayama, H.; Horiuchi, S. Adiponectin down-regulates acyl-coenzyme A:cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages. Biochem. Biophys. Res. Commun., 2004, 317, 831-836.
40. Aviram, M.; Fuhrman, B.; Maor, I.; Brook, G.J. Serotonin increases macrophage uptake of oxidized low density lipoprotein. Eur. J. Clin. Chem. Clin. Biochem., 1992, 30, 55-61.
41. Suguro, T.; Watanabe, T.; Kanome, T.; Kodate, S.; Hirano, T.; Miyazaki, A.; Adachi, M. Serotonin acts as an up-regulator of acylcoenzyme A:cholesterol acyltransferase-1 in human monocytemacrophages. Atherosclerosis, 2006, 186, 275-281.
42. Aviram, M. Platelet secretory products enhance LDL receptor activity and inhibit scavenger receptor activity in human monocyte derived macrophages. Metabolism, 1989, 38, 425-430.
43. Ouchi, N.; Kihara, S.; Arita, Y.; Nishida, M.; Matsuyama, A.; Okamoto, Y.; Ishigami, M.; Kuriyama, H.; Kishida, K.; Nishizawa, H.; Hotta, K.; Muraguchi, M.; Ohmoto, Y.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation, 2001, 103, 1057-1063.
44. Tsubakio-Yamamoto, K.; Matsuura, F.; Koseki, M.; Oku, H.; Sandoval, J.C.; Inagaki, M.; Nakatani, K.; Nakaoka, H.; Kawase, R.; Yuasa-Kawase, M.; Masuda, D.; Ohama, T.; Maeda, N.; Nakagawa-Toyama, Y.; Ishigami, M.; Nishida, M.; Kihara, S.; Shimomura, I.; Yamashita, S. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem. Biophys. Res. Commun., 2008, 375, 390-394.
45. Nobuhiko, A.; Suganuma, E.; Babaev, V.R.; Fogo, A.; Swift, L.L.; Linton, M.F.; Fazio, S.; Ichikawa, I.; Kon, V. Angiotensin II amplifies macrophage-driven atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 2143-2148.
46. Shiraishi, Y.; Watanabe, T.; Suguro, T.; Nagashima, M.; Kato, R.; Hongo, S.; Itabe, H.; Miyazaki, A.; Hirano, T.; Adachi, M. Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice. J. Hypertens., 2008, 26, 1955-1965.
47. Nagashima, M.; Watanabe, T.; Shiraishi, Y.; Morita, R.; Terasaki, M.; Arita, S.; Hongo, S.; Sato, K.; Shichiri, M.; Miyazaki, A.; Hirano, T. Chronic infusion of salusin-α and-β exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice. Atherosclerosis, 2010, 212, 70-77.
48. Okamoto, Y.; Kihara, S.; Ouchi, N.; Nishida, M.; Arita, Y.; Kumada, M.; Ohashi, K., Sakai, N.; Shimomura, I.; Kobayashi, H.; Terasaka, N.; Inaba, T.; Funahashi, T.; Matsuzawa, Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation, 2002, 106, 2767-2770.
49. Keidar, S.; Heinrich, R.; Kaplan, M.; Hayek, T.; Aviram, M. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 1464-1469.
50. Luo, N.; Liu, J.; Chung, B.H.; Yang, Q.; Klein, R.L.; Garvey, W.T.; Fu, Y. Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes, 2010, 59, 791-799.
51. Hayashi, T.; Sumi, D.; Matsui-Hirai, H.; Fukatsu, A.; Arockia, J.; Rani, P.J.A.; Kano, H.; Tsunekawa, T.; Iguchi, A. Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism. Atherosclerosis, 2003, 168, 23-31.
52. Pastore, L.; Tessitore, A.; Martinotti, S.; Toniato, E.; Alesse, E.; Bravi, M.C.; Ferri, C.; Desideri, G.; Gulino, A.; Santucci, A. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation, 1999, 100, 1646-1652.
53. Cirillo, P.; de Rosa, S.; Pacileo, M.; Gargiulo, A.; Angri, V.; Fiorentino, I.; Prevete, N.; Petrillo, G.; de Palma, R.; Leonardi, A.; de Paulis, A.; Chiariello, M. Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease. J. Thromb. Haemost., 2008, 6, 726-736.
54. Koya, T.; Miyazaki, T.; Watanabe, T.; Shichiri, M.; Atsumi, T.; Kim-Kaneyama, J.R.; Miyazaki, A. Salusin-β accelerates inflammatory responses in vascular endothelial cells via NF-κB signaling in LDL receptor-deficient mice in vivo and HUVECs in vitro. Am. J. Physiol. Heart Circ. Physiol., 2012, 303, H96-H105.
55. Li, F.; Joshua, I.G.; Lian, R.; Justus, D.E. Differing regulation of major histocompatibility class II and adhesion molecules on human umbilical vein endothelial cells by serotonin. Int. Arch. Allergy Immunol., 1997, 112, 145-151.
56. Ouchi, N.; Kihara, S.; Arita, Y.; Maeda, K.; Kuriyama, H.; Okamoto, Y.; Hotta, K.; Nishida, M.; Takahashi, M.; Nakamura, T.; Yamashita, S.; Funahashi, T.; Matsuzawa, Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 1999, 100, 2473-2476.
57. Chen, X.L.; Tummala, P.E.; Olbrych, M.T.; Alexander, R.W.; Medford, R.M. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ. Res., 1998, 83, 952-959.
58. Mikulski, Z.; Zaslona, Z.; Cakarova, L.; Hartmann, P.; Wilhelm, J.; Tecott, L.H.; Lohmeyer, J.; Kummer, W. Serotonin activates murine alveolar macrophages through 5-HT2C receptors. Am. J. Physiol. Lung Cell Mol. Physiol., 2010, 299, L272-L280.
59. Watson, A.M.; Olukman, M.; Koulis, C.; Tu, Y.; Samijono, D.; Yuen, D.; Lee, C.; Behm, D.J.; Cooper, M.E.; Jandeleit-Dahm, K.A.; Calkin, A.C.; Allen, T.J. Urotensin lI receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies inhumans and in a mouse model of diabetes. Diabetologia, 2013, 56, 1155-1165.
60. Tian, L.; Luo, N.; Zhu, X.; Chung, B.H.; Garvey, W.T.; Fu, Y. Adiponectin-AdipoR1/2-APPL1 signaling axis suppresses human foam cell formation: differential ability of AdipoR1 and AdipoR2 to regulate inflammatory cytokine responses. Atherosclerosis, 2012, 221, 66-75.
61. Kase, H.; Hattori, Y.; Jojima, T.; Okayasu, T.; Tomizawa, A.; Suzuki, K.; Banba, N.; Monden, T.; Satoh, H.; Akimoto, K.; Kasai, K. Globular adiponectin induces adhesion molecule expression through the sphingosine kinase pathway in vascular endothelial cells. Life Sci., 2007, 81, 939-943.
62. Guo, L.; Wang, M.; Zhang, Z.Y.; Hao, L.; Lou, B.Y.; Li, X.Y.; Loo, W.T.; Jin, L.; Cheung, M.N. Angiotensin II induces interleukin-6 synthesis in osteoblasts through ERK1/2 pathway via AT1 receptor. Arch. Oral Biol., 2011, 56, 205-211.
63. Ito, T.; Ikeda, U.; Shimpo, M.; Yamamoto, K.; Shimada, K. Serotonin increases interleukin-6 synthesis in human vascular smooth muscle cells. Circulation, 2000, 102, 2522-2527.
64. Johns, D.G.; Ao, Z.; Naselsky, D.; Herold, C.L.; Maniscalco, K.; Sarov-Blat, L.; Steplewski, K.; Aiyar, N.; Douglas, S.A. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn. Schmiedebergs. Arch. Pharmacol., 2004, 370, 238-250.
65. Neumeier, M.; Weigert, J.; Schäffler, A.; Wehrwein, G.; Müller-Ladner, U.; Schölmerich, J.; Wrede, C.; Buechler, C. Different effects of adiponectin isoforms in human monocytic cells. J. Leukoc. Biol., 2006, 79, 803-808.
66. Iwai, T.; Ito, S.; Tanimitsu, K.; Udagawa, S.; Oka, J. Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes. Neurosci. Res., 2006, 55, 352-360.
67. Watanabe, T.; Pakala, R.; Katagiri, T.; Benedict, C.R. Serotonin potentiates angiotensin II-induced vascular smooth muscle cell proliferation. Atherosclerosis, 2001, 159, 269-279.
68. 2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation, 1997, 96, 2280-2286.
69. Watanabe, T.; Pakala, R.; Katagiri, T.; Benedict, C.R. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation, 2001, 104, 16-18.
70. Clement, C.M.; Thomas, L.K.; Mou, Y.; Croslan, D.R.; Gibbons, G.H.; Ford, B.D. Neuregulin-1 attenuates neointimal formation following vascular injury and inhibits the proliferation of vascular smooth muscle cells. J. Vasc. Res., 2007, 44, 303-312.
71. Wang, Y.; Lam, K.S.; Xu, J.Y.; Lu, G.; Xu, L.Y.; Cooper, G.J.; Xu, A. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J. Biol. Chem., 2005, 280, 18341-18347.
72. Song, N.; Ding, W.; Chu, S.; Zhao, J.; Dong, X.; Di, B.; Tang, C. Urotensin II stimulates vascular endothelial growth factor secretion from adventitial fibroblasts in synergy with angiotensin II. Circ. J., 2012, 76, 1267-1273.
73. Cai, X.J.; Chen, L.; Li, L.; Feng, M.; Li, X.; Zhang, K.; Rong, Y.Y.; Hu, X.B.; Zhang, M.X.; Zhang, Y.; Zhang, M. Adiponectin inhibits lipopolysaccharide-induced adventitial fibroblast migration and transition to myofibroblasts via AdipoR1-AMPK-iNOS pathway. Mol. Endocrinol., 2010, 24, 218-228.
74. Xiao-jun, C.; Min, F.; Liang, C.; Li, L.; Yuan-yuan, R.; Xiao-bo, H.; Rong, W.; Ming-xiang, Z.; Yun, Z.; Mei, Z. Expression and role of adiponectin receptor 1 in lipopolysaccharide-induced proliferation of cultured rat adventitial fibroblasts. Cell Biol. Int., 2010, 34, 163-169.
75. van den Berg, E.K.; Schmitz, J.M.; Benedict, C.R.; Malloy, C.R.; Willerson, J.T.; Dehmer, G.J. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation, 1989, 79, 116-124.
76. Schieffer, B.; Schieffer, E.; Hilfiker-Kleiner, D.; Hilfiker, A.; Kovanen, P.T.; Kaartinen, M.; Nussberger, J.; Harringer, W.; Drexler, H. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation, 2000, 101, 1372-1378.
77. Hassan, G.S.; Douglas, S.A.; Ohlstein, E.H.; Giaid, A. Expression of urotensin-II in human coronary atherosclerosis. Peptides, 2005, 26, 2464-2472.
78. Zhou, Y.; Wei, Y.; Wang, L.; Wang, X.; Du, X.; Sun, Z.; Dong, N.; Chen, X. Decreased adiponectin and increased inflammation expression in epicardial adipose tissue in coronary artery disease. Cardiovasc. Diabetol., 2011, 10, 2.
79. Li, S.M.; Liu, B.; Chen, H.F. Effect of puerarin on plasma endothelin, renin activity and angiotensin II in patients with acute myocardial infarction. Zhongguo Zhong Xi Yi Jie He Za Zhi, 1997, 17, 339-341.
80. Ray, S.G.; Morton, J.J.; Dargie, H.J. Relationship of renin, angiotensin II and atrial natriuretic factor to clinical status in the early post-infarct period in patients with left ventricular dysfunction. Eur. Heart J., 1994, 15, 793-800.
81. Hojo, Y.; Ikeda, U.; Katsuki, T.; Mizuno, O.; Fukazawa, H.; Kurosaki, K.; Fujikawa, H.; Shimada, K. Release of endothelin 1 and angiotensin II induced by percutaneous transluminal coronary angioplasty. Cathet. Cardiovasc. Intervent., 2000, 51, 42-49.
82. Vikenes, K.; Farstad, M.; Nordrehaug, J.E. Serotonin is associated with coronary artery disease and cardiac events. Circulation, 1999, 100, 483-489.
83. Chai, S.B.; Li, X.M.; Pang, Y.Z.; Qi, Y.F.; Tang, C.S. Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease. Heart Vessels, 2010, 25, 138-143.
84. Heringlake, M.; Kox, T.; Uzun, O.; Will, B.; Bahlmann, L.; Klaus, S.; Eleftheriadis, S.; Armbruster, F.P.; Franz, N.; Kraatz, E. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul. Pept., 2004, 121, 129-136.
85. Simsek, Y.; Celik, O.; Yilmaz, E.; Karaer, A.; Dogan, C.; Aydin, S.; Ozer, A. Serum levels of apelin, salusin-alpha and salusin-beta in normal pregnancy and preeclampsia. J. Matern. Fetal. Neonatal. Med., 2012, 25, 1705-1708.
86. Aydin, S.; Eren, M.N.; Aydin, S.; Ozercan, I.H.; Dagli, A.F. The bioactive peptides salusins and apelin-36 are produced in human arterial and venous tissues and the changes of their levels during cardiopulmonary bypass. Peptides, 2012, 37, 233-239.
87. Shichiri, M. Reply to 'Salusins; newly identified bioactive peptides with hemodynamic and mitogenic activities.' Nat. Med., 2007, 13, 661-662.
88. 2+]i increase and neurohypophyseal hormone release from the axon terminals. J. Neuroendocrinol., 2008, 20, 207-219.
89. Gardiner, S.M.; Keyte, J.; Bennett, T. Reply to 'Salusins; newly identified bioactive peptides with hemodynamic and mitogenic activities' Nat. Med., 2007, 13, 661.
90. Sato, K.; Sato, T.; Susumu, T.; Koyama, T.; Shichiri, M. Presence of immunoreactive salusin-β in human plasma and urine. Regul. Pept., 2009, 158, 63-67.
91. El-Menyar, A.; Rizk, N.; Al Nabti.; A.D.; Hassira, S.A.; Singh, R.; Abdel Rahman, M.O.; Suwaidi, J.A. Total and high molecular weight adiponectin in patients with coronary artery disease. J. Cardiovasc. Med., 2009, 10, 310-315.
92. Matsubara, J.; Sugiyama, S.; Sugamura, K.; Nakamura, T.; Fujiwara, Y.; Akiyama, E.; Kurokawa, H.; Nozaki, T.; Ohba, K.; Konishi, M.; Maeda, H.; Izumiya, Y.; Kaikita, K.; Sumida, H.; Jinnouchi, H.; Matsui, K.; Kim-Mitsuyama, S.; Takeya, M.; Ogawa, H. A dipeptidyl peptidase-4 inhibitor, des-fluorositagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J. Am. Coll. Cardiol., 2012, 59, 265-276.
93. von Eynatten, M.; Humpert, P.M.; Bluemm, A.; Lepper, P.M.; Hamann, A.; Allolio, B.; Nawroth, P.P.; Bierhaus, A.; Dugi, K.A. High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men. Atherosclerosis, 2008, 99, 123-128.
94. Geisberg, C.A.; Wang, G.; Safa, R.N.; Smith, H.M.; Anderson, B.; Peng, X.Y.; Veerkamp, B.; Zhao, D.X.; Blakemore, D.; Yu, C.; Sawyer, D.B. Circulating neuregulin-1β levels vary according to the angiographic severity of coronary artery disease and ischemia. Coron. Artery Dis., 2011, 22, 577-582.
95. Sun, Y.M.; Su, Y.; Jin, H.B.; Li, J.; Bi, S. Sarpogrelate protects against high glucose-induced endothelial dysfunction and oxidative stress. Int. J. Cardiol., 2001, 147, 383-387.
96. Satomura, K.; Takase, B.; Hamabe, A.; Ashida, K.; Hosaka, H.; Ohsuzu, F.; Kurita, A. Sarpogrelate, a specific 5-HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease. Clin. Cardiol., 2002, 25, 28-32.
97. Fujita, M.; Mizuno, K.; Ho, M.; Tsukahara, R.; Miyamoto, A.; Miki, O.; Ishii, K.; Miwa, K. Sarpogrelate treatment reduces restenosis after coronary stenting. Am. Heart. J., 2003, 145, E16.
98. Nakamura, K.; Kariyazono, H.; Masuda, H.; Sakata, R.; Yamada, K. Effects of sarpogrelate hydrochloride on adenosine diphosphateor collagen-induced platelet responses in arteriosclerosis obliterans. Blood Coagul. Fibrinolysis, 2001, 12, 391-397.
99. Kokubu, N.; Tsuchihashi, K.; Yuda, S.; Hase, M.; Eguchi, M.; Wakabayashi, T.; Hashimoto, A.; Nakata, T.; Miura, T.; Ura, N.; Nagao, K.; Tsuzuki, M.; Wakabayashi, C.; Shimamoto, K. Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease. Circ. J., 2006, 70, 1451-1456.
100. Yamakawa, J.; Takahashi, T.; Itoh, T.; Kusaka, K.; Kawaura, K.; Wang, X.Q.; Kanda, T. A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans. Diabetes Care, 2003, 26, 2477-2478.
101. Yamakawa, J.; Takahashi, T.; Saegusa, S.; Moriya, J.; Itoh, T.; Kusaka, K.; Kawaura, K.; Wang, X.Q.; Kanda, T. Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans. J. Int. Med. Res., 2004, 32, 166-169.
102. Hayashi, K.; Sasamura, H.; Azegami, T.; Itoh, H. Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, Candesartan. J. Atheroscler. Thromb., 2012, 19, 736-746.
103. Ono, H.; Minatoguchi, S.; Watanabe, K.; Yamada, Y.; Mizukusa, T.; Kawasaki, H.; Takahashi, H.; Uno, T.; Tsukamoto, T.; Hiei, K.; Fujiwara, H. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Hypertens. Res., 2008, 31, 271-279.
104. Suzuki, T.; Nozawa, T.; Fujii, N.; Sobajima, M.; Ohori, T.; Shida, T.; Matsuki, A.; Kameyama, T.; Inoue, H. Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease. Coron. Artery Dis., 2011, 22, 352-358.
105. Vogt, L.; Chiurchiu, C.; Chadha-Boreham, H.; Danaietash, P.; Dingemanse, J.; Hadjadj, S.; Krum, H.; Navis, G.; Neuhart, E.; Parvanova, A.I.; Ruggenenti, P.; Woittiez, A.J.; Zimlichman, R.; Remuzzi, G.; de Zeeuw, D.; PROLONG (PROteinuria Lowering with urOteNsin receptor antaGonists) Study Group. Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy. Hypertension, 2010, 55, 1206-1209.
106. Sidharta, P.N.; Rave, K.; Heinemann, L.; Chiossi, E.; Krähenbühl, S.; Dingemanse, J. Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with type 2 diabetes mellitus. Br. J. Clin. Pharmacol., 2009, 68, 502-510.
107. Terasaki, M.; Nagashima, M.; Watanabe, T.; Miyazaki, A.; Hirano, T. Preventive effects of dipeptidyl peptidase-4 inhibitor on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metabolism, 2012, 61, 974-977.
108. Vittone, F.; Liberman, A.; Vasic, D.; Ostertag, R.; Esser, M.; Walcher, D.; Ludwig, A.; Marx, N.; Burgmaier, M. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. Diabetologia, 2012, 55, 2267-2275.
109. Ta, N.N.; Schuyler, C.A.; Li, Y.; Lopes-Virella, M.F.; Huang, Y. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol., 2011, 58, 157-166.
110. Arakawa, M.; Mita, T.; Azuma, K.; Ebato, C.; Goto, H.; Nomiyama, T.; Fujitani, Y.; Hirose, T.; Kawamori, R.; Watada, H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes, 2010, 59, 1030-1037.
111. Gaspari, T.; Liu, H.; Welungoda, I.; Hu, Y.; Widdop, R.E.; Knudsen, L.B.; Simpson, R.W.; Dear, A.E. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/-mouse model. Diab. Vasc. Dis. Res., 2011, 8, 117-124.
112. Sokos, G.G.; Nikolaidis, L.A.; Mankad, S.; Elahi, D.; Shannon, R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail., 2006, 12, 694-699.
113. Read, P.A.; Hoole, S.P.; White, P.A.; Khan, F.Z.; O'Sullivan, M.; West, N.E.; Dutka, D.P. A pilot study to assess whether glucagonlike peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ. Cardiovasc. Interv., 2011, 4, 266-272.
114. Read, P.A.; Khan, F.Z.; Dutka, D.P. Cardioprotection against ischemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart, 2012, 98, 408-413.
115. Gao, R.; Zhang, J.; Cheng, L.; Wu, X.; Dong, W.; Yang, X.; Li, T.; Liu, X.; Xu, Y.; Li X.; Zhou, M. A phase II, randomized, doubleblind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J. Am. Coll. Cardiol., 2010, 55, 1907-1914.
116. Jabbour, A.; Hayward, C.S.; Keogh, A.M.; Kotlyar, E.; McCrohon, J.A.; England, J.F.; Amor, R.; Liu, X.; Li, X.Y.; Zhou, M.D.; Graham, R.M.; Macdonald, P.S. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur. J. Heart Fail., 2011, 13, 83-92.
117. Kondo, K.; Shibata, R.; Unno, K.; Shimano, M.; Ishii, M.; Kito, T.; Shintani, S.; Walsh, K.; Ouchi, N.; Murohara, T. Impact of a single intracoronary administration of adiponectin on myocardial ischemia/ reperfusion injury in a pig model. Circ. Cardiovasc. Interv., 2010, 3, 166-173.
118. Hui, X.; Lam, K.S.; Vanhoutte, P.M.; Xu, A. Adiponectin and cardiovascular health: an update. Br. J. Pharmacol., 2012, 165, 574-590.